English  |  正體中文  |  简体中文  |  總筆數 :2826208  
造訪人次 :  31848499    線上人數 :  4399
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"thanigaimani p"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 1-5 / 5 (共1頁)
1 
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-08-19T00:20:40Z Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.
臺大學術典藏 2021-03-09T06:46:02Z Pembrolizumab for the treatment of advanced salivary gland carcinoma Cohen R.B.;Delord J.-P.;Doi T.;Piha-Paul S.A.;Liu S.V.;Gilbert J.;Algazi A.P.;Damian S.;Ruey-Long Hong;Le Tourneau C.;Day D.;Varga A.;Elez E.;Wallmark J.;Saraf S.;Thanigaimani P.;Cheng J.;Keam B.; Cohen R.B.; Delord J.-P.; Doi T.; Piha-Paul S.A.; Liu S.V.; Gilbert J.; Algazi A.P.; Damian S.; RUEY-LONG HONG; Le Tourneau C.; Day D.; Varga A.; Elez E.; Wallmark J.; Saraf S.; Thanigaimani P.; Cheng J.; Keam B.
臺大學術典藏 2020-05-25T07:35:07Z Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer Saraf S; Thanigaimani P; Cheng J.D; Keam B.; Mehnert J.M; Varga A; Brose M.S; Aggarwal R.R; Chia-Chi Lin; Prawira A; De Braud F; Tamura K; Doi T; Piha-Paul S.A; Gilbert J
臺大學術典藏 2020-04-10T12:51:01Z Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R.
臺大學術典藏 2020-04-10T12:51:01Z Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R.

顯示項目 1-5 / 5 (共1頁)
1 
每頁顯示[10|25|50]項目